A Structural View of the Inactivation of the SARS Coronavirus Main Proteinase by Benzotriazole Esters

Chemistry and Biology

Volumn 15, Issue 6, 2008, Pages 597-606

  Verschueren, Koen H G ^a   Pumpor, Ksenia ^a   Anemüller, Stefan ^a   Chen, Shuai ^a   Mesters, Jeroen R ^a   Hilgenfeld, Rolf ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

CHEMBIO; MICROBIO; PROTEINS

Indexed keywords

3C LIKE PROTEASE, SARS CORONAVIRUS; 3C-LIKE PROTEASE, SARS CORONAVIRUS; BENZOTRIAZOLE; CYSTEINE PROTEINASE; ESTER; PROTEINASE INHIBITOR; TRIAZOLE DERIVATIVE; VIRUS PROTEIN;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DRUG ANTAGONISM; KINETICS; METABOLISM; X RAY CRYSTALLOGRAPHY;

CATALYSIS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; ESTERS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; TRIAZOLES; VIRAL PROTEINS;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 44949215788     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.04.011     Document Type: Article

References (61)

1. pro) inhibitors. ChemBioChem 7 (2006) 1048-1055
2. Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., and Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. EMBO J. 21 (2002) 3213-3224
3. pro) structure: basis for design of anti-SARS drugs. Science 300 (2003) 1763-1767
4. Anand K., Yang H., Bartlam M., Rao Z., and Hilgenfeld R. Coronavirus main proteinase: target for antiviral drug therapy. In: Schmidt A., Wolff M.H., and Weber O. (Eds). Coronaviruses with Special Emphasis on First Insights Concerning SARS (2005), Birkhäuser, Basel 173-199
5. Arbour N., Day R., Newcombe J., and Talbot P.J. Neuroinvasion by human respiratory coronaviruses. J. Virol. 74 (2000) 8913-8921
6. pro. Biochemistry 43 (2004) 4906-4912
7. Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., and Baker S.C. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 79 (2005) 15189-15198
8. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
9. Chen L., Gui C., Luo X., Yang Q., Gunther S., Scandella E., Drosten C., Bai D., He X., Ludewig B., et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces viral replication in vitro. J. Virol. 79 (2005) 7095-7103
10. Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K., Jiang H., and Shen X. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. J. Biol. Chem. 280 (2005) 164-173
11. Chiu S.S., Chan K.H., Hu K.W., Kwan S.W., Guan Y., Poon L.L., and Peiris J.S. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin. Infect. Dis. 40 (2005) 1721-1729
12. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA
13. Dixon M., and Webb E.C. The Enzymes. Third Edition (1979), Longman, London
14. Drosten C., Günther S., Preiser W., van der Werf S., Brodt H.-R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A.M., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1978
15. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
16. Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y., Chen J., et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 279 (2004) 1637-1642
17. Fouchier R.A.M., Hartwig N.G., Bestebroer T.M., Niemeyer B., de Jong J.C., Simon J.H., and Osterhaus A.D.M.E. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. USA 101 (2004) 6212-6216
18. Goetz D.H., Choe Y., Hansell E., Chen Y.T., McDowell M., Jonsson C.B., Roush W.R., McKerrow J., and Craik C.S. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry 46 (2007) 8744-8752
19. Graziano V., McGrath W.J., Yang L., and Mangel W.F. SARS-CoV main proteinase: the monomer-dimer equilibrium dissociation constant. Biochemistry 45 (2006) 14632-14641
20. Hegyi A., and Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 83 (2002) 595-599
21. Hilgenfeld R., and Pumpor K. Sometimes intermediates do the job. Chem. Biol. 13 (2006) 235-236
22. Hirel P.H., Schmitter M.J., Dessen P., Favat G., and Blanquet S. Extent of N-terminal excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid. Proc. Natl. Acad. Sci. USA 86 (1989) 8247-8251
23. Hsu M.F., Kuo C.J., Chang K.T., Chang H.C., Chou C.C., Ko T.P., Chang G.G., Wang A.H., and Liang P.H. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280 (2005) 31257-31266
24. Hsu W.C., Chang H.C., Chou C.Y., Tsai P.J., Lin P.I., and Chang G.G. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main proteinase. J. Biol. Chem. 280 (2005) 22741-22748
25. Kaeppler U., Stiefl N., Schiller M., Vicik R., Breuning A., Schmitz W., Rupprecht D., Schmuck C., Baumann K., Ziebuhr J., et al. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. J. Med. Chem. 48 (2005) 6832-6842
26. Knowles S.R., Phillips E.J., Dresser L., and Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. 37 (2003) 1139-1142
27. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
28. Kuo C.-J., Chi Y.-H., Hsu J.T.-A., and Liang P.-H. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem. Biophys. Res. Commun. 318 (2004) 862-867
29. Kupfer B., Simon A., Jonassen C.M., Viazov S., Ditt V., Tillmann R.L., Muller A., Matz B., and Schildgen O. Two cases of severe obstructive pneumonia associated with an HKU1-like coronavirus. Eur. J. Med. Res. 12 (2007) 134-138
30. Lau S.K.P., Woo P.C.Y., Yip C.C.Y., Tse H., Tsoi H.-W., Cheng V.C.C., Lee P., Tang B.S.F., Cheung C.H.Y., Lee R.A., et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J. Clin. Microbiol. 44 (2006) 2063-2071
31. Lee T.-W., Cherney M.M., Huitema C., Liu J., James K.E., Powers J.C., Eltis L.D., and James M.N.G. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J. Mol. Biol. 353 (2005) 1137-1151
32. Lee T.-W., Cherney M.M., Liu J., James K.E., Powers J.C., Eltis L.D., and James M.N.G. Crystal structures reveal an induced-fit binding of a substrate-like aza-peptide epoxide to SARS coronavirus main peptidase. J. Mol. Biol. 366 (2007) 916-932
33. Lindner H.A., Fotouhi-Ardakani N., Lytvyn V., Lachance P., Sulea T., and Ménard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 79 (2005) 15199-15208
34. Lu I.-L., Mahindroo N., Liang P.-H., Peng Y.-H., Kuo C.-J., Tsai K.-C., Hsieh H.-P., Chao Y.-S., and Wu S.-Y. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory coronavirus main protease. J. Med. Chem. 49 (2006) 5154-5161
35. McIntosh K., Dees J.H., Becker W.B., Kapikian A.Z., and Chanock R.M. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. USA 57 (1967) 933-940
36. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
37. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
38. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., Nicholls J., Yee W.K.S., Cheung M.T., Cheng V.C., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
39. Pyrc K., Dijkman R., Deng L., Jebbing M.F., Ross H.A., Berkhout B., and van der Hoek L. Mosaic structure of human coronavirus NL63, one thousand years of evolution. J. Mol. Biol. 364 (2006) 964-973
40. Schmidt M.F., Isidro-Llobet A., Lisurek M., El-Dahshan A., Tan J., Hilgenfeld R., and Rademann J. Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening. Angew. Chem. Int. Ed. Engl. 47 (2008) 3275-3278
41. Shi J., Wei Z., and Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J. Biol. Chem. 279 (2004) 24765-24773
42. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177 (1972) 705-706
43. Stockman L.J., Bellamy R., and Garner P. SARS: systematic review of treatment effects. PLoS Med. 3 (2006) e343
44. pro) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354 (2005) 25-40
45. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weißbrich B., Snijder E.J., Rabenau H., Doerr H.W., et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84 (2003) 2305-2315
46. Tian W.X., and Tsou C.L. Determination of the rate constants of enzyme modification by measuring the substrate reaction in the presence of the modifier. Biochemistry 21 (1982) 1028-1032
47. Tsai K.C., Chen S.Y., Liang P.H., Lu I.L., Mahindroo N., Hsieh H.P., Chao Y.S., Liu L., Liu D., Lien W., et al. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem. 49 (2006) 3485-3495
48. Tsukada H., and Blow D.M. Structure of α-chymotrypsin refined at 1.68 Å resolution. J. Mol. Biol. 184 (1985) 703-711
49. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
50. van der Hoek L., Pyrc K., Jebbing M.F., Vermeulen-Oost W., Berkhout R.J., Wolthers K.C., Wertheim-van Dillen P.M., Kaandorp J., Spaargaren J., and Berkhout B. Identification of a new human coronavirus. Nat. Med. 10 (2004) 368-373
51. Walker P.A., Leong L.E., Ng P.W., Tan S.H., Waller S., Murphy D., and Porter A.G. Efficient and rapid affinity purification of proteins using recombinant fusion proteases. Biotechnology (NY) 12 (1994) 601-605
52. Woo P.C.Y., Lau S.K.P., Chu C.-M., Chan K.-H., Tsoi H.-W., Huang Y., Wong B.H.L., Poon R.W.S., Cai J.J., Luk W.-K., et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79 (2005) 884-895
53. Wu C.-Y., Jan J.-T., Ma S.-H., Kuo C.-J., Juan H.-F., Cheng Y.-S.E., Hsu H.-H., Huang H.-C., Wu D., Brik A., et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA 101 (2004) 10012-10017
54. Wu C.-Y., King K.-Y., Kuo C.-J., Fang J.-M., Wu Y.-T., Ho M.-Y., Liao C.-L., Shie J.-J., Liang P.-H., and Wong C.-H. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. Chem. Biol. 13 (2006) 261-268
55. Xu T., Ooi A., Chen L., Wilmouth R., Liu D.X., and Lescar J. Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer. Acta Crystallogr. F61 (2005) 964-966
56. pro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol. 366 (2007) 965-975
57. Xue X., Yu H., Yang H., Xue F., Wu Z., Shen W., Li J., Zhou Z., Ding Y., Zhao Q., et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol. 82 (2008) 2515-2527
58. Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., Sun L., Mo L., Ye S., Pang H., et al. The crystal structures of severe acute respiratory syndrome virus main proteinase and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 100 (2003) 13190-13195
59. Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao O., Zhou Z., Pei D., Ziebuhr J., et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3 (2005) e324
60. Ziebuhr J., Herold J., and Siddell S.G. Characterization of a human coronavirus (strain 229E) 3C-like proteinase activity. J. Virol. 69 (1995) 4331-4338
61. Ziebuhr J., Snijder E.J., and Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in Nidovirales. J. Gen. Virol. 81 (2000) 853-879